Bulgarian drug maker Sopharma sales dip 12% y/y in Aug

The company registered 6% year-on-year growth in domestic sales in the month under review. Exports, however, dropped by an annual 21%, it said in a bourse filing.

Sopharma's sales in the first eight months of 2022 rose by 35%, driven by 37% growth in domestic sales and a 35% rise in exports, the company also said.

The drug producer reported last week a consolidated net profit of 43.4 million levs ($21.95 million/22.19 million euro) in the first half of 2022, up from 32.2 million levs a year earlier. Revenue in the six-month period climbed to 810.5 million levs from 771.2 million levs a year earlier.

By 1431 CEST on Wednesday, shares in Sopharma traded by 0.88% lower at 4.48 levs on the Bulgarian Stock Exchange.

(1 euro = 1.95583 levs)